Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Trojer

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Bioorganic & Medicinal Chemistry Letters|May 18, 2017
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitorsJun Liang, Sharada Labadie, Birong Zhang, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Nature Chemical Biology|May 24, 2016
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cellsMaia Vinogradova, Victor S Gehling, Amy Gustafson, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Bioorganic & Medicinal Chemistry Letters|May 18, 2017
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitorsJun Liang, Sharada Labadie, Birong Zhang, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Nature Chemical Biology|May 24, 2016
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cellsMaia Vinogradova, Victor S Gehling, Amy Gustafson, et al.
Pageof 6